Prevention of contrast-induced nephropathy in STEMI patients undergoing primary percutaneous coronary intervention: A systematic review

Journal of Interventional Cardiology

Volumn 26, Issue 1, 2013, Pages 97-105

  Busch, Sarah Victoria EkelØf ^a   Jensen, Svend Eggert ^b   Rosenberg, Jacob ^a   Gögenur, Ismail ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; PLACEBO; RECOMBINANT HUMAN BRAIN NATRIURETIC PEPTIDE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR RISK; CONTRAST INDUCED NEPHROPATHY; EMBASE; HEART CATHETERIZATION; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; KIDNEY FAILURE; MEDLINE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACETYLCYSTEINE; ACUTE KIDNEY INJURY; CONTRAST MEDIA; FLUID THERAPY; FREE RADICAL SCAVENGERS; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PERCUTANEOUS CORONARY INTERVENTION; RECOMBINANT PROTEINS;

EID: 84874107136     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/joic.12007     Document Type: Article

References (41)

1. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. J Am Med 1997; 103: 368-375. (Pubitemid 27506242)
2. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264. (Pubitemid 34535335)
3. Best PJ, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-1119. (Pubitemid 34267412)
4. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004; 44: 1780-1785. (Pubitemid 39424075)
5. Wi J, Ko YG, Kim JS, et al. Impact of contrast-induced acute kidney injury with transient or persistent renal dysfunction on long-term outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart 2011; 97: 1753-1757.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ann Intern Med 2009; 151: W65-W94.
7. Tanaka A, Suzuki Y, Suzuki N, et al. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction ? Intern Med 2011; 50: 673-677.
8. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006; 354: 2773-2782. (Pubitemid 43974195)
9. Droppa M, Desch S, Blase P, et al. Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty. Clin Res Cardiol 2011; 100: 1037-1043.
10. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2010; 55: 2201-2209.
11. Aslanger E, Uslu B, Akdeniz C, et al. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty. Coron Artery Dis 2012; 23: 265-270.
12. Jaffery Z, Verma A, White CJ, et al. A randomized trial of intravenous N-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. Catheter Cardiovasc Interv 2012; 79: 921-926.
13. Zhang J, Fu X, Jia X, et al. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention. Acta Radiol 2010; 51: 641-648.
14. Maioli M, Toso A, Leoncini M, et al. Effects of hydration in contrast-induced acute kidney injury after primary angioplasty: A randomized, controlled trial. Circ Cardiovasc 2011; 4: 456-462.
15. Bolognese L, Falsini G, Schwenke C, et al. Impact of iso-osmolar versus low-osmolar contrast agents on contrast-induced nephropathy and tissue reperfusion in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 2012; 109: 67-74.
16. Drager LF, Andrade L, Barros de Toledo JF, et al. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: Decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 2004; 19: 1803-1807. (Pubitemid 38961391)
17. Lopez BL, Snyder JW, Birenbaum DS, et al. N-acetylcysteine enhances endothelium-dependent vasorelaxation in the isolated rat mesenteric artery. Ann Emerg Med 1998; 32: 405-410. (Pubitemid 28495767)
18. Heyman SN, Goldfarb M, Shina A, et al. N-acetylcysteine ameliorates renal microcirculation: Studies in rats. Kidney Int 2003; 63: 634-641. (Pubitemid 36126809)
19. Fishbane S, Durham JH, Marzo K, et al. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am Soc Nephrol 2004; 15: 251-260. (Pubitemid 38140765)
20. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004; 25: 206-211. (Pubitemid 38235156)
21. Trivedi H, Daram S, Szabo A, et al. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 2009; 122: 874.e9-15.
22. Gonzales DA, Norsworthy KJ, Kern SJ, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: Unsupervised clustering to resolve heterogeneity. BMC Med 2007; 5: 32.
23. Kelly AM, Dwamena B, Cronin P, et al. Meta-analysis: Effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008; 148: 284-294. (Pubitemid 351665489)
24. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: Main results from the randomized acetylcysteine for contrast-induced nephropathy trial (ACT). Circulation 2011; 124: 1250-1259.
25. Burger AJ,. A review of the renal and neurohormonal effects of B-type natriuretic peptide. Congest Heart Fail 2005; 11: 30-38.
26. Elkayam U, Akhter MW, Liu M, et al. Assessment of renal hemodynamic effects of nesiritide in patients with heart failure using intravascular Doppler and quantitative angiography. JACC Cardiovasc Imaging 2008; 1: 765-771.
27. Jensen KT, Carstens J, Pedersen EB,. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998; 274: F63-F72.
28. Chen HH, Cataliotti A, Schirger JA, et al. Local renal delivery of a natriuretic peptide: A renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. J Am Coll Cardiol 2009; 53: 1302-1308.
29. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94: 3184-3189. (Pubitemid 26427485)
30. Nunag M, Brogan M, Garrick R,. Mitigating contrast-induced acute kidney injury associated with cardiac catheterization. Cardiol Rev 2009; 17: 263-269.
31. Persson PB, Hansell P, Liss P,. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68: 14-22. (Pubitemid 43181360)
32. Jo S-H, Youn T-J, Koo B-K, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: The RECOVER study: A randomized controlled trial. J Am Coll Cardiol 2006; 48: 924-930. (Pubitemid 44308573)
33. McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006; 48: 692-699. (Pubitemid 44175706)
34. Barrett BJ, Carlisle EJ,. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 1993; 188: 171-178. (Pubitemid 23183119)
35. Kanei Y, Ayabe K, Ratcliffe J, et al. The impact of iso-osmolar contrast use in emergent percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Invasive Cardiol 2011; 23: 448-450.
36. Heinrich MC, Häberle L, Müller V, et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: Meta-analysis of randomized controlled trials. Radiology 2009; 250: 68-86.
37. Reed M, Meier P, Tamhane UU, et al. The relative renal safety of iodixanol compared with low-osmolar contrast media: A meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2009; 2: 645-654.
38. Heinrich MC, Häberle L, Müller V, et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: Meta-analysis of randomized controlled trials. Radiology. 2009; 250 (1): 68-86.
39. Moran SM, Myers BD,. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int 1985; 27: 928-937. (Pubitemid 15035559)
40. Levy EM, Viscoli CM, Horwitz RI,. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-1494. (Pubitemid 26140761)
41. Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events: Cause and effect ? Clin J Am Soc Nephrol 2009; 4: 1162-1169.